.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Novartis
AstraZeneca
QuintilesIMS
UBS
Cipla
Cantor Fitzgerald
Julphar
Cerilliant

Generated: January 16, 2018

DrugPatentWatch Database Preview

Patents Expiring in August 2016

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Galderma Labs LpORACEAdoxycyclineCAPSULE;ORAL050805-001May 26, 2006RXYesYes➤ Subscribe➤ SubscribeYTREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
Galderma Labs LpORACEAdoxycyclineCAPSULE;ORAL050805-001May 26, 2006RXYesYes➤ Subscribe➤ SubscribeYTREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
Glaxo Grp LtdADVAIR DISKUS 100/50fluticasone propionate; salmeterol xinafoatePOWDER;INHALATION021077-001Aug 24, 2000RXYesYes➤ Subscribe➤ Subscribe
GlaxosmithklineSEREVENTsalmeterol xinafoatePOWDER;INHALATION020692-001Sep 19, 1997RXYesYes➤ Subscribe➤ Subscribe
Glaxo Grp LtdFLOVENT DISKUS 50fluticasone propionatePOWDER;INHALATION020833-001Sep 29, 2000RXYesYes➤ Subscribe➤ Subscribe
Glaxo Grp LtdFLOVENT DISKUS 250fluticasone propionatePOWDER;INHALATION020833-003Sep 29, 2000RXYesYes➤ Subscribe➤ Subscribe
Glaxo Grp LtdFLOVENT DISKUS 100fluticasone propionatePOWDER;INHALATION020833-002Sep 29, 2000RXYesYes➤ Subscribe➤ Subscribe
Glaxo Grp LtdADVAIR DISKUS 500/50fluticasone propionate; salmeterol xinafoatePOWDER;INHALATION021077-003Aug 24, 2000RXYesYes➤ Subscribe➤ Subscribe
Glaxo Grp LtdADVAIR DISKUS 250/50fluticasone propionate; salmeterol xinafoatePOWDER;INHALATION021077-002Aug 24, 2000RXYesYes➤ Subscribe➤ Subscribe
ApilENABLEXdarifenacin hydrobromideTABLET, EXTENDED RELEASE;ORAL021513-002Dec 22, 2004ABRXYesYes➤ Subscribe➤ SubscribeYTREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Cipla
Federal Trade Commission
QuintilesIMS
Fish and Richardson
McKinsey
Chubb
Johnson and Johnson
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot